Metropolis Healthcare Ltd (METROPOLIS) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Metropolis Healthcare reported 12% year-on-year revenue growth for FY25, reaching INR 345 crores in Q4, a 10% year-on-year increase. Growth was driven by a 6% rise in patient volumes and contributions from pricing and test mix improvements.
- Three acquisitions were completed: Core Diagnostics (oncology testing), Scientific Pathology (Agra), and Dr. Ahujas' Pathology and Imaging Center (Dehradun). These acquisitions are expected to increase North India's revenue contribution from 8% to 14-15% in FY26.
- Adjusted EBITDA for FY25 increased by 14% to INR 325 crores. Q4 adjusted EBITDA was INR 84 crores, impacted by one-time acquisition-related expenses of INR 21 crores.
- The company's strategic focus for the future includes accelerated expansion of collection centers, enhancing productivity, improving operational efficiency, and geographical diversification.
- Metropolis aims to expand margins by approximately 100 basis points going forward.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.